Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Biotechnology

Healthcare
$42.92 -1.86%

-$0.62 today

Market cap
$808.18M
Beta
1.18
P/E (TTM)
1.7
EPS (TTM)
$19.78
52W Low $18.14High $52.24

Volume 0.24M

Average 0.36M

Income Statement

Follow revenue through to earnings.

Revenue

$294.28M

FY 2025 · Annual

+64.1% YoY

Operating Income

$125.47M

FY 2025 · Annual

+418.6% YoY

Net Income

$367.02M

FY 2025 · Annual

+1999.1% YoY

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue149.24M120.24M116.88M179.28M294.28M
Cost of Revenue1.08M1.75M7.11M18.65M19.62M
Gross Profit148.15M118.49M109.77M160.63M274.66M
Gross Margin99.3%98.5%93.9%89.6%93.3%
Research & Development65.24M60.27M24.52M23.38M33.3M
Selling, General & Admin91.89M112.45M105.74M113.06M115.9M
Operating Expenses160.65M174.04M130.26M136.44M149.2M
Depreciation & Amortization1.16M998K1.24M2.23M2.42M
EBITDA(11.29M)(53.87M)(16.98M)28.51M131.56M
EBITDA Margin-7.6%-44.8%-14.5%15.9%44.7%
Operating Income(12.5M)(55.55M)(20.49M)24.19M125.47M
Operating Margin-8.4%-46.2%-17.5%13.5%42.6%
Interest Income47K684K2.27M2.09M3.68M
Interest Expense4.86M3.71M6.87M7.92M7.32M
Other Income / Expenses(4.81M)(3.02M)(4.6M)(5.83M)(3.64M)
Income Before Tax(17.31M)(58.57M)(25.09M)18.37M121.83M
Pre-Tax Margin-11.6%-48.7%-21.5%10.2%41.4%
Income Tax Expense605K00881K(245.2M)
Net Income(17.91M)(58.57M)(25.09M)17.49M367.02M
Net Margin-12.0%-48.7%-21.5%9.8%124.7%
EPS (Basic)(1.10)(3.40)(1.44)0.9920.40
EPS (Diluted)(1.10)(3.40)(1.44)0.9919.48
Weighted Avg Shares17.05M17.24M17.4M17.58M17.99M
Weighted Avg Shares (Diluted)17.05M17.24M17.4M17.69M18.84M

RIGL Earnings Waterfall · TTM

NASDAQ:RIGL · Revenue to Net Income

Key Ratios

EPS$18.72
Gross Margin93.1%
Net Margin124.4%
P/E Ratio5.3
P/S Ratio7.5

Analysis

$299.8M of revenue converted into $364.2M of net income for the selected period. Gross margin is 93.1% and net margin is 124.4%, showing how much revenue survives after costs and taxes. EPS is $18.72, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 13, 2026
SC 13GSC 13G filingNov 10, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
4Statement of changes in beneficial ownershipSep 3, 2026

How much revenue does RIGL generate?

Rigel Pharmaceuticals, Inc. (RIGL) reported $294.28M of revenue in fiscal 2025.

Is RIGL profitable?

Rigel Pharmaceuticals, Inc. (RIGL) reported $367.02M of net income, with a net margin of 124.7%.